Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy
dc.contributor.author | Cengiz, Muhammet | |
dc.contributor.author | Seckin, Yuksel | |
dc.contributor.author | Cagin, Yasir Furkan | |
dc.contributor.author | Cengiz, Ayse Nuransoy | |
dc.date.accessioned | 2024-08-04T19:42:39Z | |
dc.date.available | 2024-08-04T19:42:39Z | |
dc.date.issued | 2021 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Aim: This study aimed to investigate the frequency at which physicians test hepatitis B virus (HBV) serology before treatment and the rate of hepatitis B virus reactivation (HBVr) after treatment in patients undergoing chemotherapy (CT) due to a solid organ malignancy (SOM) or hematological malignancy (HM). Materials and Methods: Baseline clinical feature, HBV serology, and liver function test data for 1275 patients ? 18 years of age who underwent CT for the first time due to various SOMs and HMs from 2015-2017 were obtained from the database and retrospectively analyzed. HBV serology was studied in 296 (201 HM, 95 SOM) of the 1275 patients retrieved from the database. Results: The prevalence of HBV was 9.5% (121 patients). Only 49 (40.4%) HBV-positive patients had HBV DNA. Of those, 72 (59.5%) underwent prophylactic antiviral therapy. HBVr was detected in only 3 patients (1.5%), and all of those patients had HMs and were recommended oral antiviral therapy but did not. Conclusion: In patients with SOMs, the screening rates of HBV serology, as well as prophylaxis and follow-up HMs were extremely low. Therefore, these patients should be screened for HBV serology and prophylactic treatment should be given when necessary for HBVr. | en_US |
dc.identifier.doi | 10.5455/annalsmedres.2021.02.189 | |
dc.identifier.endpage | 2064 | en_US |
dc.identifier.issn | 2636-7688 | |
dc.identifier.issue | 11 | en_US |
dc.identifier.startpage | 2059 | en_US |
dc.identifier.trdizinid | 482786 | en_US |
dc.identifier.uri | https://doi.org/10.5455/annalsmedres.2021.02.189 | |
dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/482786 | |
dc.identifier.uri | https://hdl.handle.net/11616/88552 | |
dc.identifier.volume | 28 | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Annals of Medical Research | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy | en_US |
dc.type | Article | en_US |